open access

Vol 9, No 5 (2004)
Published online: 2004-01-01
Submitted: 2004-03-25
Get Citation

Rituximab as immunotherapy following autologous stem cell transplantation (ASCT) in a 17-year-old boy with diffuse large B cell lymphoma – a case report

Agnieszka Zaucha-Prażmo, Jolanta Stefaniak, Agnieszka Brodzisz, Beata Wójcik, Katarzyna Drabko, Marta Chroma, Jerzy R. Kowalczyk
DOI: 10.1016/S1507-1367(04)71026-3
·
Rep Pract Oncol Radiother 2004;9(5):179-182.

open access

Vol 9, No 5 (2004)
Published online: 2004-01-01
Submitted: 2004-03-25

Abstract

Rituximab is a human-mouse chimeric monoclonal antibody with specifity for the CD20 antigen expressed on B-lineage cells.

We are reporting a 17-year old boy diagnosed with diffuse large B cell lymphoma, CD20(+). He was treated by standard chemotherapy and megachemotherapy with ASCT. The boy relapsed in the mediastinum and lungs one year after the treatment was completed. He underwent secondary treatment: surgical procedure, chemotherapy and immunotherapy with rituximab, second ASCT and again immunotherapy in the post-transplantation period. No severe complications during the treatment with rituximab were observed except for leukopenia and central venous catheter infection.

The CT scans performed one year after the therapy was completed showed regression of changes previously observed.

Abstract

Rituximab is a human-mouse chimeric monoclonal antibody with specifity for the CD20 antigen expressed on B-lineage cells.

We are reporting a 17-year old boy diagnosed with diffuse large B cell lymphoma, CD20(+). He was treated by standard chemotherapy and megachemotherapy with ASCT. The boy relapsed in the mediastinum and lungs one year after the treatment was completed. He underwent secondary treatment: surgical procedure, chemotherapy and immunotherapy with rituximab, second ASCT and again immunotherapy in the post-transplantation period. No severe complications during the treatment with rituximab were observed except for leukopenia and central venous catheter infection.

The CT scans performed one year after the therapy was completed showed regression of changes previously observed.

Get Citation

Keywords

rituximab; stem cell transplantation; B cell lymphoma

About this article
Title

Rituximab as immunotherapy following autologous stem cell transplantation (ASCT) in a 17-year-old boy with diffuse large B cell lymphoma – a case report

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 9, No 5 (2004)

Pages

179-182

Published online

2004-01-01

DOI

10.1016/S1507-1367(04)71026-3

Bibliographic record

Rep Pract Oncol Radiother 2004;9(5):179-182.

Keywords

rituximab
stem cell transplantation
B cell lymphoma

Authors

Agnieszka Zaucha-Prażmo
Jolanta Stefaniak
Agnieszka Brodzisz
Beata Wójcik
Katarzyna Drabko
Marta Chroma
Jerzy R. Kowalczyk

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl